You are here

P&T News

March 13

Researchers say this real-world study in Canada should also apply to the U.S.
The results from a seven-year study were “entirely unexpected”
Generic competition pushed back to at least mid-2018
Report identifies critical need to minimize financial toxicity and increase access
Nearly 64% achieved healthy levels after barbers promoted follow-up

March 12

Regeneron, Sanofi offer price reductions
Sollpura didn’t meet noninferiority endpoint versus Pancreaze
Cardiovascular death, heart failure hospitalization decrease
In one case, a required postmarket surveillance study hasn’t even started

March 8

Insurers, PBMs respond by blaming drug-makers for steep prices
Injectable Trogarzo targets multidrug-resistant disease
St. Jude Medical valve aids in treatment of birth defects
A negative result in the 23andMe test doesn’t rule out increased cancer risk
Steps needed to mass-produce vaccines using cell-based and other technologies

March 6

Shorter course of therapy may increase patients’ treatment adherence
Lanadelumab reduced monthly attack rates and improved quality of life in study
American College of Physicians ups A1c limit to 8%
Drug is first FDA-approved PD-1 inhibitor to offer every-four-week dosing
Findings challenge common practice of increasing doses at early signs of worsening symptoms

March 5

One-time chief of Turing Pharmaceuticals may be out a Picasso